Advertisement

Platelet activation and inflammatory response in patients with non-dipper hypertension

      Abstract

      Objective

      Non-dipper hypertensives had about three times the risk of atherosclerotic events than hypertensives whose blood pressure was >10% lower at night compared to daytime (dippers). Platelet activation and inflammatory response may derive from most atherosclerotic events. Mean platelet volume (MPV) is a determinant of platelet activation and high sensitive C-reactive protein (hs-CRP) is the best candidate assay to identify and monitor the inflammatory response. We aimed to determine whether MPV and hs-CRP levels are elevated in non-dipper patients compared to dippers and healthy controls. In addition, we tried to find out if MPV and CRP are related to each other or not in non-dipper hypertensives.

      Method

      The total 126 patients study group included 86 patients with hypertension and 40 healthy subjects (16 male, mean age; 51 ± 4) as control. Ambulatory blood pressure monitoring was performed for all patients. Hypertensive patients were divided into two groups; 46 dipper patients (18 male, mean age; 50 ± 9) and 40 non-dipper patients (17 male, mean age; 53 ± 11). Clinical baseline characteristics were similar between groups. We measured mean platelet volume in a blood sample collected in EDTA tubes and high-sensitive CRP was measured by using BN2 model nephlometer.

      Results

      Non-dipper patients demonstrated higher levels of MPV compared to dippers and normotensives (9.72 ± 0.52 fl vs 9.38 ± 0.33 fl and 8.92 ± 0.42 fl, p < 0.05, respectively). High-sensitive CRP levels were also significantly higher in non-dippers compared to dippers and normotensives (4.9 ± 1.7 mg/l vs 3.8 ± 1.5 mg/l and 2.7 ± 0.8 mg/l, p < 0.05, respectively). There was significant positive correlation between MPV and CRP levels (p = 0.002, r = 0.482) in non-dipper hypertensives.

      Conclusion

      Our results suggest that patients with non-dipping tend to have increased platelet activation and inflammatory response. Increased platelet activation and inflammatory response could contribute to increase the atherosclerotic risk in non-dipper patients compared to dippers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hermida R.C.
        Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
        Chronobiol Int. 2007; 24: 749-775
        • Verdecchia P.
        • Schillaci G.
        • Guerrieri M.
        • et al.
        Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension.
        Circulation. 1990; 81: 528-536
        • Shimada K.
        • Kawamoto A.
        • Matsubayahi K.
        • Mishinaga M.
        • Kimura S.
        • Ozawa T.
        Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension.
        J Hypertens. 1992; 10: 875-878
        • Fukuda M.
        • Munemura M.
        • Usami T.
        • et al.
        Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy.
        Kidney Int. 2004; 65: 621-625
        • Baumgart P.
        • Walger P.
        • Gemen S.
        • von Eiff M.
        • Raidt H.
        • Rahn K.H.
        Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation.
        Nephron. 1991; 57: 293-298
        • Takakuwa H.
        • Ise T.
        • Kato T.
        • et al.
        Diurnal variation of hemodynamic indices in non-dipper hypertensive patients.
        Hypertens Res. 2001; 24: 195-201
        • Seo H.S.
        • Kang T.S.
        • Park S.
        • et al.
        Non-dippers are associated with adverse cardiac remodeling and dysfunction.
        In J Cardiol. 2006; 112: 171-177
        • Tsiara S.
        • Elisaf M.
        • Jagroop I.A.
        • Mikhailidis D.P.
        Platelets as predictor of vascular risk: is there a practical index of platelet activity?.
        Clin Appl Thromb Hemost. 2003; 9: 177-190
        • Thombson C.B.
        • Eaton K.
        • Princiotta S.M.
        • Rushin C.A.
        • Valeri C.R.
        Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function.
        Br J Haematol. 1982; 50: 509-519
        • Cameron H.A.
        • Phillips R.
        • Ibbotson R.M.
        • Carson P.H.
        Platelet size in myocardial infarction.
        Br Med J. 1983; 287: 449-451
        • Pizzulli L.
        • Yang A.
        • Martin J.F.
        • Lüderitz B.
        Changes in platelet size and count in unstable angina pectoris compared to stable or non-cardiac chest pain.
        Eur Heart J. 1998; 19: 80-84
        • Celik T.
        • Yuksel U.C.
        • Iyisoy A.
        • et al.
        Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol.
        Int J Cardiol. 2007; 116: 206-211
        • Bath P.
        • Algert C.
        • Chapman N.
        • Neal B.
        PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of CVD.
        Stroke. 2004; 35: 622-626
        • Park Y.
        • Schoene N.
        • Haris W.
        Mean platelet volume as an indicator of platelet activation: methodological issues.
        Platelets. 2002; 13: 301-306
        • Martin J.F.
        • Bath P.M.
        • Burr M.L.
        Influence of platelet size on outcome after myocardial infarction.
        Lancet. 1991; 338: 1409-1411
        • Pabón Osuna P.
        • Nieto Ballesteros F.
        • Moríñigo Muñoz J.L.
        • et al.
        The effect of mean platelet volume on the short term prognosis of acute myocardial infarction.
        Res Esp Cardiol. 1998; 51: 816-822
        • Pearson T.A.
        • Mensah G.A.
        • Alexander R.W.
        • et al.
        Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association.
        Circulation. 2003; 107: 499-511
        • Ridker P.M.
        Clinical application of C-reactive protein for cardiovascular disease detection and preventation.
        Circulation. 2003; 107: 363-369
        • Joint National Committee
        The seventh report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC 7).
        J Am Med Assoc. 2003; 289: 2560-2572
        • Kannel W.B.
        Blood pressure as a cardiovascular risk factor: prevention and treatment.
        JAMA. 1996; 275: 1571-1576
        • Verdecchia P.
        • Schillaci G.
        • Reboldi G.
        • Franklin S.S.
        • Porcellati C.
        Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension.
        Circulation. 2001; 103: 2579-2584
        • Verdecchia P.
        • Reboldi G.
        • Porcellati C.
        • et al.
        Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subject.
        J Am Coll Cardiol. 2002; 39: 878-885
        • Martin J.F.
        • Trowbridge E.A.
        • Salmon G.
        • Plumb J.
        The biological significance of platelet volume; its relationship to bleeding time, TXA2 production and megakaryocyte nuclear DNA concentration.
        Thromb Res. 1983; 32: 443-460
        • Erhart S.
        • Beer J.H.
        • Reinhart W.H.
        Influence of aspirin on platelet count and volume in human.
        Acta Haematol. 1999; 101: 140-144
        • Nadar S.K.
        • Blann A.D.
        • Kamath S.
        • Beevers D.G.
        • Lip G.Y.
        Platelet indexes in relation to target organ damage in high risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
        J Am Coll Cardiol. 2004; 44: 415-422
        • Giles C.
        • Inglis T.C.
        Thrombocytopenia and macrothrombocytosis in gestational hypertension.
        Br J Obstet Gynaecol. 1981; 88: 1115-1119
        • Coban E.
        • Yazıcıoglu G.
        • Avcı A.B.
        • Akcıt F.
        The mean platelet volume in patients with essential and white coat hypertension.
        Platelets. 2005; 16: 435-438
        • Tavil Y.
        • Sen N.
        • Yazici H.U.
        • Hizal F.
        • Abaci A.
        • Cengel A.
        Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease.
        Thromb Res. 2007; 120: 245-250
        • Libby P.
        • Ridker P.M.
        • Maseri A.
        Inflammation and atherosclerosis.
        Circulation. 2002; 105: 1135
        • Buffon A.
        • Biasucci L.M.
        • Liuzzo G.
        • D’Onofrio G.
        • Crea F.
        • Maseri A.
        Widespread coronary inflammation in unstable angina.
        N Engl J Med. 2002; 347: 5-12
        • Clearfield M.B.
        C-reactive protein: a new risk assessment tool for cardiovascular disease.
        J Am Osteopath Assoc. 2005; 105: 409-416
        • Tsioufis C.
        • Syrseloudis D.
        • Dimitriadis K.
        • et al.
        Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension.
        J Hum Hypertens. 2008; 22: 501-508
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Von Hundelshausen P.
        • Weber K.S.
        • et al.
        RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
        Circulation. 2001; 103: 1772-1777
        • Brody J.I.
        • Pickering N.J.
        • Capuzzi D.M.
        • Fink G.B.
        • Can C.A.
        • Gomez F.
        Interleukin-1 as a factor in occlusive vascular disease.
        Am J Clin Pathol. 1992; 97: 8-13
        • Simon D.I.
        • Chen Z.
        • Xu H.
        • et al.
        Platelet glycoprotein Ib is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18).
        J Exp Med. 2000; 192: 193-204
        • Dastjerdi M.S.
        • Emami T.
        • Najafian A.
        • Amini M.
        Mean platelet volume measurement, EDTA or citrate?.
        Hematology. 2006; 11: 317-319
        • Macey M.
        • Azam U.
        • McCarthy D.
        • et al.
        Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system.
        Clin Chem. 2002; 48: 891-899